Related Experiment Videos
Supplement use among men with prostate cancer
Jeremy B Wiygul1, Brian R Evans, Bercedis L Peterson
1Division of Urology, Duke University Medical Center, Durham, North Carolina 27710, USA. wiygu001@mc.duke.edu
Urology
|July 5, 2005
Summary
A majority of men with prostate cancer use dietary supplements, with use increasing after diagnosis. Those who are white, more educated, and lead healthy lifestyles are more likely to use supplements.
Area of Science:
- Oncology
- Nutritional Science
- Public Health
Background:
- Prostate cancer is a significant health concern for men.
- Dietary supplement use is prevalent in the general population and among cancer patients.
- Understanding supplement use patterns in prostate cancer patients is crucial for comprehensive care.
Purpose of the Study:
- To characterize the patterns of dietary supplement use among men diagnosed with prostate cancer.
- To identify demographic and behavioral factors associated with supplement use.
- To examine changes in supplement use following a prostate cancer diagnosis.
Main Methods:
- A survey was mailed to 1402 men diagnosed with prostate cancer at Duke University Medical Center between 1997 and 2002.
- The survey collected data on health status, education, diet, exercise, smoking, and supplement intake.
- Statistical analyses were performed to compare subgroups and assess changes in supplement use.
Main Results:
- Of 805 respondents, 73% reported using supplements, with multivitamins, vitamin E, vitamin C, and calcium being most common.
- Supplement use increased significantly after diagnosis for most products.
- Use was higher among white, more educated men, those who exercise regularly, and those consuming ≥5 daily servings of fruits and vegetables.
Conclusions:
- A high proportion of men with prostate cancer use dietary supplements.
- Supplement use is associated with specific demographic (white, higher education) and lifestyle (regular exercise, healthy diet) factors.
- Systematic data collection on supplement use is needed to evaluate their impact on prostate cancer outcomes, as current evidence of benefit post-diagnosis is lacking.